Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2017年 / 59卷 / 1529期
关键词：
FIXED-RATIO COMBINATION; LIRAGLUTIDE IDEGLIRA; EFFICACY; OUTCOMES; DEGLUDEC; TRIAL;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：147 / 149
页数：3
相关论文
共 50 条
  • [31] Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring
    Kawaguchi, Yuji
    Hajika, Yuriko
    Rinka, Maho
    Masumoto, Koji
    Sawa, Jun
    Hamazaki, Kenji
    Kumeda, Yasuro
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (05) : 598 - 607
  • [32] Improved postprandial glycaemic control in Type 2 diabetes with a combination of insulin degludec and liraglutide: results from a meal test
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L.
    Bode, B. W.
    DIABETIC MEDICINE, 2014, 31 : 61 - 61
  • [33] Postprandial glycaemic control in patients with Type 2 diabetes on a combination of insulin degludec and liraglutide vs each component individually
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L. H.
    Bode, B. W.
    DIABETIC MEDICINE, 2014, 31 : 51 - 51
  • [34] Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
    Åsa Ericsson
    Adam Lundqvist
    Applied Health Economics and Health Policy, 2017, 15 : 237 - 248
  • [35] Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
    Ericsson, Asa
    Lundqvist, Adam
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 237 - 248
  • [36] Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial
    Kaku, Kohei
    Araki, Eiichi
    Tanizawa, Yukio
    Agner, Bue Ross
    Nishida, Tomoyuki
    Ranthe, Mattis
    Inagaki, Nobuya
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2674 - 2683
  • [37] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
    Evans, Marc
    Billings, Liana K.
    Hakan-Bloch, Jonas
    Slothuus, Ulla
    Abrahamsen, Trine J.
    Andersen, Andreas
    Jansen, Jeroen P.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347
  • [38] Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
    Dardano, Angela
    Bianchi, Cristina
    Del Prato, Stefano
    Miccoli, Roberto
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 465 - 475
  • [39] Insulin degludec: Effects on Quality of Life in Type 2 Diabetes
    Kulzer, B.
    Wilhelm, B.
    Hermanns, N.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (04): : 241 - 249
  • [40] Recent advances with insulin degludec for the treatment of Type 2 diabetes
    Stokes, Victoria
    Gough, Stephen C. L.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (04) : 301 - 312
12345